Like you say POS, it all depends on NNZ2566 working, end of year is not that far away.....
So then when we look at the Board and management to bring us through, there is top-shelf and very impressive line up in the team.
Dr Tregues holds long term international business building in Pharma FDA approvals.
Bruce Hancox has long term experience through Brierley that would hold us well in maximising SP.
Larry Glass leading US business development to drive FDA action ticks a huge box for me.
Senior management is simarly star-studded.
Funding would not seem to be an issue, so we just come back to the point of NNZ2566 and other developments coming through their trials. Very exciting! GLTA
The Case for Yes, page-44
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.68 |
Change
-0.100(0.48%) |
Mkt cap ! $2.643B | |||
| Open | High | Low | Value | Volume |
| $20.50 | $20.74 | $20.01 | $5.091M | 247.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156 | $20.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.68 | 256 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |